Written and maintained by CASRAI Editorial Board
Last updated
Youden’s J index is J = sensitivity + specificity − 1, and the cutpoint that maximizes it — the point on the ROC curve farthest above the diagonal — is the most commonly used rule for turning a continuous test score into a binary positive/negative call. It is also, by construction, the point where a false positive and a false negative are treated as equally costly and equally likely to occur. That assumption is convenient and is often wrong: a missed cancer and an unnecessary biopsy are not the same mistake, and a screening test applied to a low-prevalence population behaves very differently at the “optimal” Youden cutpoint than the same test used to confirm a diagnosis in a referred, high-risk population. This guide covers what J actually measures, how to compute and report it, the equal-cost assumption it silently makes, and the alternative threshold-selection criteria — cost-weighted, closest-to-(0,1), and constrained-sensitivity/specificity — that are the correct choice once costs or prevalence are lopsided.
What Youden’s J index is
For a diagnostic or classification test evaluated against a reference standard at a given cutpoint, Youden’s J is defined directly from sensitivity and specificity:
J = Sensitivity + Specificity − 1
Because sensitivity is the true positive rate and specificity is the true negative rate, J ranges from −1 (a test that is wrong every time) through 0 (a test that performs no better than chance, e.g. sensitivity 0.5 and specificity 0.5) to 1 (a test with zero false positives and zero false negatives at that cutpoint). J = 0 is the diagonal “line of no discrimination” on an ROC curve; J at any given cutpoint is exactly the vertical distance from that diagonal up to the ROC curve at that point. Maximizing J over every possible cutpoint is therefore the same operation as finding the single point on the ROC curve that sits farthest above the diagonal — geometrically, the point where a line parallel to the diagonal (slope 1) is tangent to the curve.
The index is named for W. J. Youden, who proposed it in 1950 as a single summary number for comparing diagnostic tests (“Index for Rating Diagnostic Tests,” Cancer, 1950). The same formula had appeared earlier, in a different context, in Charles Sanders Peirce’s 1884 paper in Science — it is occasionally called the Peirce–Youden index for that reason, though “Youden’s J” or “Youden index” is by far the more common name in the clinical and biostatistics literature.
A worked example
The mechanics are easiest to see in a small illustrative table — hypothetical counts, not a reported result from any real study. Suppose a test is evaluated at three candidate cutpoints against a reference standard in 200 patients (100 truly positive, 100 truly negative):
| Cutpoint | Sensitivity | Specificity | J |
|---|---|---|---|
| Low (permissive) | 0.95 | 0.55 | 0.50 |
| Middle | 0.85 | 0.80 | 0.65 |
| High (strict) | 0.60 | 0.94 | 0.54 |
The middle cutpoint has the highest J (0.65) and would be reported as the Youden-optimal threshold. Note what that choice implicitly does: it treats the 15-point gain in specificity moving from low to middle (55% → 80%) as worth the same as the 10-point loss in sensitivity (95% → 85%), and it treats the further move from middle to high the same way in reverse. If a false negative at this cutpoint means a missed diagnosis with serious downstream consequences, that trade may not be the one a clinician or a study team actually wants.
The assumption Youden’s J makes, and why it matters
J gives sensitivity and specificity equal weight. That is only the right criterion when two conditions both hold: a false positive and a false negative carry roughly equal cost or consequence, and the population being tested has roughly balanced numbers of true positives and true negatives (or, more precisely, the pretest odds are close to what the reference study used). Neither condition is guaranteed, and in a lot of real research and clinical settings, neither holds:
- Screening a low-prevalence population. A test optimized for J on a case-control or referral-clinic sample (often close to 50% prevalence by design) will not behave the same way when applied to a general population where the true prevalence might be 1–2%. The Youden cutpoint doesn’t adjust for this shift on its own — predictive values move with prevalence even though sensitivity and specificity, in principle, don’t.
- Asymmetric consequences. Missing a treatable cancer (false negative) is usually judged far worse than an unnecessary follow-up test (false positive). A triage or screening rule built on J will under-weight sensitivity relative to what the actual decision problem calls for.
- The reverse case. A confirmatory test that triggers an irreversible, high-risk intervention (surgery, a drug with serious side effects) may need specificity weighted far more heavily than sensitivity — the opposite direction, but still a case where equal weighting is wrong.
- Downstream classification metrics. If the threshold feeds into a reclassification analysis — see Net Reclassification Improvement — an arbitrarily equal-weighted cutpoint can distort the reclassification numbers in either direction depending on which error type the intervention is more sensitive to.
None of this means J is a bad statistic — it is a fast, assumption-transparent default that is genuinely appropriate whenever costs really are close to symmetric, or when a single index is needed to compare the discriminative ability of two tests independent of any specific decision threshold. The problem is treating it as the automatically “correct” or “optimal” cutpoint regardless of the decision it feeds into.
Alternative threshold-selection criteria for unequal costs
When the equal-cost assumption doesn’t hold, several other criteria pick a different point on the same ROC curve. All of them require the same underlying data (the full sensitivity/specificity pairs across cutpoints) — the difference is only in which point on the curve gets selected.
Cost-weighted (decision-theoretic) threshold
The formal decision-theoretic solution selects the cutpoint where the slope of the ROC curve equals a ratio built from the relative costs of the two error types and the disease prevalence:
slope = [(1 − prevalence) / prevalence] × [Cost(false positive) / Cost(false negative)]
Youden’s J is the special case of this formula where the cost ratio is 1 and prevalence is 0.5, which is exactly why it defaults to equal weighting. Estimating real cost ratios is rarely exact, but even a rough one — “a missed case is roughly five times worse than an unnecessary follow-up” — moves the selected cutpoint in a defensible, documented direction instead of leaving the equal-weighting assumption unstated. This approach traces to classic ROC decision theory (associated with C.E. Metz’s work on ROC analysis) and is the criterion of choice whenever a study team can put even an approximate number on the relative cost of the two error types.
Closest-to-(0,1) / Euclidean distance
This criterion picks the cutpoint whose point on the ROC curve is geometrically closest to the top-left corner (0,1) — the hypothetical perfect test, with 100% sensitivity and 100% specificity:
minimize √[(1 − sensitivity)² + (1 − specificity)²]
In practice this frequently lands on a similar cutpoint to Youden’s J, but not always identically — the two criteria are geometrically different (perpendicular distance to the diagonal vs. Euclidean distance to a corner) and can diverge meaningfully on asymmetric or irregularly shaped ROC curves. Like J, it still implicitly treats the two axes as equally important; it doesn’t solve the unequal-cost problem on its own, but some analysts prefer it as a geometric alternative that behaves slightly differently on curves with an unusual shape.
Concordance probability (product) method
Instead of the sum used by J, this method maximizes the product of sensitivity and specificity rather than their sum. It tends to penalize a cutpoint that achieves a high J by pushing one of the two statistics very low (e.g. sensitivity 0.99, specificity 0.30) more than J does, because a very small factor drags the product down sharply. It is a useful sanity check alongside J rather than a full replacement when costs are genuinely unequal, since it still doesn’t incorporate an actual cost ratio — it just changes how “balance” is defined.
Fixed-sensitivity or fixed-specificity constraint
Often the most practically defensible approach in applied research: instead of optimizing a combined index at all, fix a minimum acceptable sensitivity (e.g. “this screening test must catch at least 95% of true cases”) or a minimum acceptable specificity, and report the best cutpoint that satisfies that constraint. This sidesteps the need to estimate a numeric cost ratio and instead encodes the clinical or policy judgment directly as a constraint, which is easier to defend, audit, and pre-register than an implicit equal-weighting assumption.
Reporting the threshold-selection method
Whichever criterion is used, the method itself needs to be stated explicitly, not left implicit as “the optimal cutpoint.” STARD and TRIPOD+AI, the current reporting standards for diagnostic accuracy and prediction-model studies, both call for the threshold-selection method to be pre-specified and reported alongside the resulting sensitivity/specificity pair — a cutpoint chosen post hoc to maximize J (or any other criterion) on the same data used to report performance inflates the apparent accuracy and should be flagged as such, ideally validated on an independent sample. If the threshold comes out of a fitted model rather than a single biomarker — for example a logistic regression predicted probability — the same threshold-selection logic applies to the predicted-probability cutoff, not just to a raw lab value.
Frequently asked questions
What counts as a “good” Youden’s J value?
There is no universal cutoff, but as a rough orientation: values below about 0.3 generally indicate weak discrimination, 0.3–0.6 moderate, and above 0.6 strong — these are informal conventions, not a validated classification scheme, and should always be interpreted against the specific test and clinical context rather than treated as a pass/fail threshold.
Is Youden’s index the same thing as Youden’s J?
Yes — “Youden’s index” and “Youden’s J statistic” (or simply “J”) refer to the same quantity, sensitivity + specificity − 1.
Does maximizing Youden’s J always give the same cutpoint as maximizing accuracy?
Not in general. Overall accuracy is weighted by how common each class actually is in the sample, so in an imbalanced sample the accuracy-maximizing cutpoint can differ from the J-maximizing one, which ignores prevalence by construction (it only uses sensitivity and specificity, each computed within its own class).
Can Youden’s J be negative?
Yes, if sensitivity + specificity is less than 1 at that cutpoint — meaning the test is doing worse than chance at that particular point, which can happen away from the optimal cutpoint even for a test that performs reasonably well overall.
How does prevalence affect which cutpoint is “optimal”?
Sensitivity and specificity are, in principle, properties of the test rather than the population, so the mathematically Youden-optimal cutpoint doesn’t shift with prevalence on its own. But the real-world cost ratio usually does shift with prevalence — a low-prevalence screening setting generates far more false positives per true positive at any fixed cutpoint, which is exactly the situation the cost-weighted criterion above is designed to account for and J is not.
Related CASRAI guides
For the underlying 2×2 table, predictive values, and likelihood ratios that J is built from, see Sensitivity vs. Specificity. For the models that typically generate the continuous score being thresholded, see Logistic Regression (the Logit Model). For how a chosen threshold interacts with model-comparison metrics, see Net Reclassification Improvement. For reporting requirements around the threshold-selection method itself, see STARD and TRIPOD+AI. Browse the full Research Methods & Statistics hub for related quantitative-analysis guides.
